世卫组织和诺沃·诺迪斯克公司承诺790万美元用于中低收入国家防治肥胖症和糖尿病。 WHO and Novo Nordisk commit $7.9M to fight obesity, diabetes in low- and middle-income countries.

世卫组织基金会和诺沃·诺迪斯克组织扩大了伙伴关系,承诺提供790万美元,用于防治肥胖和糖尿病等心血管新陈代谢疾病,重点是中低收入国家的预防、早期发现和初级保健。 The WHO Foundation and Novo Nordisk have expanded their partnership with a $7.9 million commitment to combat cardio-renal-metabolic diseases like obesity and diabetes, focusing on prevention, early detection, and primary care in low- and middle-income countries. 资金将分两个阶段提供,2024年提供290万美元,2025年12月提供500万美元。 Funding will be delivered in two phases, with $2.9 million in 2024 and $5 million in December 2025. 这项努力支持加强全球保健系统,并在发起印度光之光倡议解决学校儿童肥胖问题的路线图期间得到强调。 The effort supports global health system strengthening and was highlighted during the launch of the Shine India initiative’s roadmap to address childhood obesity in schools. 合作的目的是为地方干预提供基于证据的工具,针对影响到10亿以上人口的全球负担。 The collaboration aims to provide evidence-based tools for local interventions, targeting a global burden affecting over 1 billion people.